Peptide Therapeutics Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Innovative and Generic), By Peptide Type (Native Peptides, Analog Peptides, and Heterologous Peptides), By Technology Type (Liquid Phase, Solid phase, and Hybrid),  By Therapeutic Area (Cancer, Cardiovascular Diseases, Central Nervous Systems, Metabolic Disorders, Infections, Hematological Disorders, Gastrointestinal Disorders, Dermatology, Respiratory Disorders, Acromegaly, and Others), and Region Forecast 2019-2030

The peptide therapeutics market size was valued at USD 43,753.6 million in 2023 and is expected to grow at a CAGR of 5.8% over the forecast year to reach USD 64,925.2 million in 2030. Peptide therapies are oligomers or polypeptides, constituting short chains of amino acids. The therapeutic application of peptide medicines times back to the use of antibiotics like gramicidin derived from Bacillus brevis by Dubos in 1939. It was applied in the treatment of anthrax. Afterward, their use increased as peptide therapy imitators the multitude of roles naturally occurring peptides play in the body including hormones, growth factors, neurotransmitters, ion channel ligands, and anti-infective properties.

 Moreover, the human body can degrade them, thereby making them safe and relatively easy to tolerate. The market advances in peptide therapy are growing very quickly due to the demand for targeted treatments and the increased prevalence of chronic conditions such as diabetes and cancer. There is continued enhancement in new developments in synthesis technology and drug delivery technologies. Contempt these developments, regulatory hurdles and production costs often delay the delivery of newly approved peptide drugs. 

There is a higher possibility in personalized medicine, a field that has lately been gaining momentum, and on which investors and pharmaceutical companies can ride the wave for the elimination of rare diseases. Furthermore, peptides are not used as drugs nowadays but in combination with other medicines to seek increased efficacy

Peptide Therapeutics Market Key Developments

• In June 2018, the discovery of new peptide therapies to treat obesity and diabetes is the goal of a research partnership and option agreement between Novo Nordisk and Kallyope Inc. Peptide's business was able to grow thanks to this strategy, which also accelerated the company's growth.
• In January 2018, Washington University School of Medicine in St. Louis was the partner with Sun Pharmaceuticals Ltd., which contributed USD 10 million. Small-molecule medications based on peptides, oligonucleotides, and hormones were developed with the help of this partnership to treat common illnesses. The corporation was able to diversify its product line as a result.